Vision: Equitable access to health treatments proven effective for targeted populations
Mission: Support biopharmaceutical clients as they shape, substantiate, and realize product and portfolio value with unequaled science, methodology, expertise, and commitment
Who we are
The impact of Health Technology Assessment (HTA) as a driver of reform in Europe, Canada, and Australia was well recognized at the end of the last century. The emerging importance of HTA and Comparative Effectiveness Research to the overwhelming majority of health systems since then means that the demand for scientific evidence to substantiate health product value is paramount. It was in this dynamic environment of access based on evidence that HERON was founded, to support biopharmaceutical manufacturers through a purposely rigorous process toward the goal of commercial market access. The environment was complex in HERON's launch year (1999) and that complexity continues to grow.
The science and methodology that grounded HERON's approach to systematic reviews and other components of the HTA submission process have been perfected over the years, with HERON becoming one of the world's largest independent providers of evidence in support of value. As access to world markets became even more complicated and competitive, HERON responded by aligning evidence review, health economics modeling, and value message/global dossier development with strategic capabilities in pricing, reimbursement, and market access. This milestone occurred in 2008 and has subsequently positioned HERON to translate unparalleled evidence into optimized market access.
HERON is still fully owned by the three original co-founders, John Kerrigan, Chris Knight and Paul Howard, and since its launch in 1999, growth has occurred geographically as well as strategically for HERON, with worldwide consultancy services provided from three continents. A burgeoning operation in the US, accompanied by significant offshore capacity with focused expertise in evidence development, has put HERON in high growth mode. With 150 scientists, statisticians, health economists, global access strategists, and quality assurance specialists, HERON maintains resolute focus on the definition, substantiation, and realization of product value as a strategic partner to a broad array of biopharmaceutical corporations.
What we do
HERON is an evidence-based life sciences consultancy with expertise in the commercial development, launch, and sustainability of health products. The consulting partner of choice to biopharmaceutical clients globally, HERON shapes, substantiates, and realizes product and portfolio value within the context of constant change in the healthcare landscape.
Why it matters
Value and effectiveness are as important to the commercial success of a health product as efficacy and safety. Whether it's pricing and reimbursement strategy to successfully navigate access challenges, or quantifying value in a highly competitive market, HERON's scientific methodologies and broad-based expertise are time tested and industry respected, supporting informed decision-making throughout the discovery, development, and delivery lifecycle.